Pacira BioSciences is urging shareholders to vote for its three board nominees ahead of the June 9, 2026 annual meeting, warning that electing even one nominee from activist investor DOMA Perpetual could disrupt the company's strong growth momentum. Independent proxy advisors ISS, Glass Lewis, and Egan-Jones recommend supporting Pacira's nominees due to the company's record financial results, robust non-opioid pain therapy portfolio, and promising clinical pipeline. Pacira criticizes DOMA's nominees as underqualified and warns their plans could harm innovation and lead to a fire sale of the business. Shareholders are encouraged to vote using Pacira's BLUE proxy card to maintain the current board's strategy and long-term value creation.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
